Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Reich, Kristian; Armstrong, April W.; Foley, Peter; Song, Michael; Wasfi, Yasmine; Randazzo, B.; Li, Shu; Shen, Yaung‐Kaung; Gordon, Kenneth B.

doi:10.1016/j.jaad.2016.11.042

articleJournal of the American Academy of DermatologyJan 4, 2017HYBRID OA

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

KRKristian Reich AWApril W. Armstrong PFPeter Foley MSMichael Song YWYasmine Wasfi

Dermatologikum Hamburg · University of Southern California · +5 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Background

Phase II data suggested that guselkumab, an anti-interleukin-23 monoclonal antibody, was efficacious in psoriasis.

Objective

We sought to assess efficacy and safety of guselkumab in moderate to severe psoriasis versus placebo and adalimumab, including interrupted treatment and switching adalimumab nonresponders to guselkumab.

Citation impact

724

total citations

FWCI: 34.88
Percentile: 100%
References: 32

Citations per year

Authors

9

Topics & keywords

Topics

Keywords

Medicine
Psoriasis Area and Severity Index
Adalimumab
Psoriasis
Placebo
Internal medicine
Randomized controlled trial
Dermatology Life Quality Index

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.